News about "Lupin"

Lupin Limited Secures US FDA Approval for Generic Brivaracetam Oral Solution

Lupin has received US FDA approval for its generic brivaracetam oral solution, bioequivalent to Briviact, and has launched the product in the US market targeting partial-onset seizures.

Lupin | 25/02/2026 | By News Bureau

Lupin Secures European Commission Approval for Ranluspec, Biosimilar Ranibizumab

European Commission clears Lupin’s biosimilar ranibizumab, Ranluspec, for multiple retinal disorders; Sandoz to commercialise across the EU, expanding access to affordable biologics.

Lupin | 24/02/2026 | By News Bureau

Lupin Posts 37 percent Q3 Profit Growth on Record US Sales

Lupin Limited reported a 37.4 percent year-on-year increase in net profit for the third quarter ended December 31, 2025, reaching INR 1,180.5 crore, compared with INR 858.9 crore in the same quarter last year.

Lupin | 13/02/2026 | By Darshana |  120

Lupin Resolves Mirabegron Patent Dispute with Astellas in USD 90 Million Settlement

Lupin Limited has reached a USD 90 million settlement to resolve a patent dispute with Japan-based Astellas Pharma concerning Lupin’s generic version of mirabegron, a treatment for overactive bladder. The agreement concludes ongoing litigation in the United States and provides commercial clarity around Lupin’s continued participation in the market.

Lupin | 11/02/2026 | By Darshana

Lupin Launches Topiramate Extended-Release Capsules in US Following FDA Approval

Lupin rolls out FDA-approved generic topiramate extended-release capsules in the US for epilepsy and migraine treatment.

Lupin | 05/02/2026 | By News Bureau |  104

Lupin Partners with Galenicum to Commercialise Injectable Semaglutide

Global pharmaceutical major Lupin Limited has entered into a licensing and supply agreement with Galenicum Health, S.L.U. through its subsidiary, Lupin Atlantis Holdings SA (LAHSA), for finished injectable formulations of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.

Lupin | 21/01/2026 | By Darshana |  133

Lupin Inks Exclusive Licensing Deal with Neopharmed for Plasil in Brazil and Philippines

Global pharmaceutical major Lupin Limited said its subsidiaries in the Philippines, Multicare Pharmaceuticals, and in Brazil, MedQuimica, have entered into an exclusive licensing agreement with Italy-based Neopharmed Gentili S.p.A. to market and promote the gastroenterology brand Plasil (metoclopramide) in their respective markets.

Lupin | 19/12/2025 | By Darshana |  174

Lupin Secures Positive CHMP Opinion for Ranibizumab Biosimilar

Lupin has received a positive opinion from the CHMP for its ranibizumab biosimilar, supported by comprehensive analytical similarity data and a global Phase III clinical trial involving 600 patients with neovascular Age-related Macular Degeneration (AMD).

Lupin | 18/12/2025 | By News Bureau |  110

Lupin Receives Tentative US FDA Nod for Siponimod Tablets, Generic to Novartis' Mayzent

Lupin has received tentative approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Siponimod Tablets in strengths of 0.25 mg, 1 mg and 2 mg.

Lupin | 05/12/2025 | By Dineshwori |  267

Lupin and Valorum Enter into Licensing Agreement for Armlupeg in US

Under the terms of the agreement, Valorum will advance the commercialisation and distribution of Armlupeg (pegfilgrastim-unne) in the US. Lupin will be responsible for manufacturing and supply of the product and will receive an upfront licence fee and a royalty payment on net sales.

Lupin | 05/12/2025 | By Dineshwori